Product Information
TERAZOSIN 2 MG CAPSULE is a generic product labeled by Chartwell RX LLC, priced at $0.1055 per EA under NDC 62135045990. Its NADAC has been published 178 times since May 10, 2023.
FDA first approved this application on Jan 30, 2001. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2 mg/1
Manufacturer
Chartwell RX LLCNDC
62135045990
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TERAZOSIN HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA075614FDA Approved
1/30/2001
TE Code
AB
On Market Since
4/30/2021
Pharmacological Classes
Price Statistics
The NADAC for TERAZOSIN 2 MG CAPSULE has been published 178 times since May 10, 2023, and over the history we have for it it has declined 20.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1055 per EA |
|---|---|
| All-time high | $0.1535 (Mar 13, 2024) |
| All-time low | $0.1029 (Aug 19, 2026) |
| 52-week high | $0.1210 |
| 52-week low | $0.1029 |
| Median price | $0.1346 |
| Average price | $0.1301 |
| Largest weekly change | -16.1% (Apr 17, 2024) |
| Weeks tracked | 178 |
| Tracking since | May 10, 2023 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Chartwell RX LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Terazosin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
alpha-Adrenergic Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TERAZOSIN 2 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for TERAZOSIN 2 MG CAPSULE, manufactured by Chartwell RX LLC, is $0.1055 per EA (NDC 62135045990), effective Sep 30, 2026.
How has the price of TERAZOSIN 2 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for TERAZOSIN 2 MG CAPSULE has declined 20.7%. It has been tracked across 178 weekly CMS publications since May 10, 2023.
What are the highest and lowest recorded NADAC prices for TERAZOSIN 2 MG CAPSULE?
Since May 10, 2023, the NADAC for TERAZOSIN 2 MG CAPSULE has ranged from a low of $0.1029 (Aug 19, 2026) to a high of $0.1535 (Mar 13, 2024), with a median of $0.1346 per EA.
Are there cheaper alternatives to TERAZOSIN 2 MG CAPSULE?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as TERAZOSIN 2 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures TERAZOSIN 2 MG CAPSULE?
TERAZOSIN 2 MG CAPSULE (NDC 62135045990) is labeled by Chartwell RX LLC, and CMS classifies it as a generic product.